Comparing SG&A Expenses: Amneal Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: Amneal vs. Arrowhead Pharmaceuticals

__timestampAmneal Pharmaceuticals, Inc.Arrowhead Pharmaceuticals, Inc.
Wednesday, January 1, 20148461500024419536
Thursday, January 1, 201510967900034718089
Friday, January 1, 201611875700040998209
Sunday, January 1, 201710904600032022880
Monday, January 1, 201823043500019110051
Tuesday, January 1, 201928959800026556257
Wednesday, January 1, 202032672700052275890
Friday, January 1, 202136550400080981000
Saturday, January 1, 2022399700000124431000
Sunday, January 1, 202342967500090932000
Monday, January 1, 202498761000
Loading chart...

Unleashing the power of data

SG&A Expenses: A Tale of Two Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry players is crucial. Amneal Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amneal's SG&A expenses surged by over 400%, peaking at approximately $430 million in 2023. This reflects a strategic investment in scaling operations and market presence. In contrast, Arrowhead's SG&A expenses grew more modestly, increasing by around 270% to nearly $91 million in 2023. This suggests a more conservative approach, possibly focusing on niche markets or innovative R&D. Notably, data for 2024 is incomplete, highlighting the dynamic nature of financial planning in this sector. These trends underscore the diverse strategies companies employ to navigate the ever-evolving pharmaceutical landscape.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025